Millenia gives hope to Mali
Millenia Hope, a Delaware Biopharma corporation, has now sold 10,000 treatments of MMH Malarex/MMH 18 to a private clinic in Mali. The sale constitutes the initial order from a second contract that could also generate sales of 100,000 treatments over the next 12 months.
Millenia Hope, a Delaware Biopharma corporation, has now sold 10,000 treatments of MMH Malarex/MMH 18 to a private clinic in Mali. The sale constitutes the initial order from a second contract that could also generate sales of 100,000 treatments over the next 12 months.
On 10 August Millenia announced its initial African sale of 25,000 treatments from a contract totalling 100,000 treatments spread over the following 12 months.
'There are 300-500 million malaria-infected individuals globally; three million die annually, of which one million are children under five years of age,' said Leonard Stella, ceo. 'An effective malaria cure is urgently needed. In many regions, 70% or more of malaria strains are resistant to existing medications and the WHO is no longer funding products like chloroquine to which malaria is resistant.'